Forte Biosciences, Inc. (FBRX)

Data as of Aug 27, 2026, from SEC Form 4 filings.

No open-market insider trades (90d)Watch FBRX

See up to 3 months of FBRX. The 7-day demo opens the 1M and 3M ranges and puts FBRX on your watchlist.

Latest FBRX insider trades

Antony A. Riley - Officer
Open-market purchase$125K
Nov 21, 2024
Steven Kornfeld - Director
Other3,960 sh
Aug 27, 2026
Steven Kornfeld - Director
Derivative

About Forte Biosciences, Inc. (FBRX)

The SEC lists Forte Biosciences, Inc. under CIK 0001419041, in pharmaceutical preparations. It is grouped with Health Care companies on this site.

Sector: Health Care

SEC filings for FBRX on EDGAR

FBRX Form 4 activity by transaction type, last 90 days

Form 4 transaction type	Transactions	Shares	Total value
Derivative transaction	58	2,858,758
Other acquisition / disposition	4	137,982

Dollar totals cover purchases and sales only (codes P and S). Grants, option exercises, gifts and tax withholding are counted in shares, because none of them is a trade at a market price.

FBRX insider transactions (Form 4)

105

30 Form 4 filings on record, the earliest from Oct 2, 2024, newest first.

Date	Insider	Transaction	Security	Shares	Price	Value
Aug 27, 2026	Steven Kornfeld - Director	Other	Common Stock	3,960	-^{footnote F1}	-
Aug 27, 2026	Steven Kornfeld - Director	Derivative	Stock Option (right to buy)	1,200	-^{footnote F2}	-
Aug 27, 2026	Steven Kornfeld - Director	Derivative	Stock Option (right to buy)	800	-^{footnote F2}	-
Aug 27, 2026	Steven Kornfeld - Director	Derivative	Stock Option (right to buy)	1,000	-^{footnote F2}	-
Aug 27, 2026	Steven Kornfeld - Director	Derivative	Stock Option (right to buy)	1,000	-^{footnote F2}	-
Aug 27, 2026	Steven Kornfeld - Director	Derivative	Stock Option (right to buy)	1,000	-^{footnote F2}	-
Aug 27, 2026	Steven Kornfeld - Director	Derivative	Stock Option (right to buy)	2,000	-^{footnote F2}	-
Aug 27, 2026	Steven Kornfeld - Director	Derivative	Stock Option (right to buy)	31,000	-^{footnote F2}	-
Aug 27, 2026	Steven Kornfeld - Director	Derivative	Restricted Stock Units	18,353	-^{footnote F4}	-
Footnote F1 (price): Pursuant to the Agreement and Plan of Merger, dated July 26, 2026 (the "Merger Agreement"), by and among Forte Biosciences, Inc. ("Company"), argenx BV ("Parent"), and Avena Merger Sub Inc., a wholly owned subsidiary of Parent ("Purchaser"), the shares of common stock of Company… Full note on SEC EDGAR Footnote F2 (price): Pursuant to the Merger Agreement, each unexercised and outstanding option to purchase shares of Common Stock (a "Company Option"), whether or not vested, and which had a per share exercise price that was less than the Merger Consideration, was canceled and converted into the… Full note on SEC EDGAR Footnote F4 (price): Pursuant to the Merger Agreement, each outstanding restricted stock unit (a "Company RSU"), whether or not vested, was canceled and converted into the right of the holder to receive (i) (subject to any applicable withholding taxes) a lump-sum cash payment equal to (x) the Merger… Full note on SEC EDGAR
Aug 27, 2026	Scott C. Brun - Director	Derivative	Stock Option (right to buy)	2,000	-^{footnote F1,F2}	-
Aug 27, 2026	Scott C. Brun - Director	Derivative	Stock Option (right to buy)	1,000	-^{footnote F1,F2}	-
Aug 27, 2026	Scott C. Brun - Director	Derivative	Stock Option (right to buy)	2,000	-^{footnote F1,F2}	-
Aug 27, 2026	Scott C. Brun - Director	Derivative	Stock Option (right to buy)	31,000	-^{footnote F1,F2}	-
Aug 27, 2026	Scott C. Brun - Director	Derivative	Restricted Stock Units	18,353	-^{footnote F4}	-
Footnote F1 (price): Pursuant to the Agreement and Plan of Merger, dated July 26, 2026 (the "Merger Agreement"), by and among Forte Biosciences, Inc. ("Company"), argenx BV ("Parent"), and Avena Merger Sub Inc., a wholly owned subsidiary of Parent ("Purchaser"), each unexercised and outstanding… Full note on SEC EDGAR Footnote F2 (price): At the effective time of the Merger, each Company Option that is then outstanding and unexercised, whether or not vested and which has a per share exercise price that is equal to or greater than the Merger Consideration, shall be cancelled with no consideration payable therefor. Footnote F4 (price): Pursuant to the Merger Agreement, each outstanding restricted stock unit (a "Company RSU"), whether or not vested, was canceled and converted into the right of the holder to receive (i) (subject to any applicable withholding taxes) a lump-sum cash payment equal to (x) the Merger… Full note on SEC EDGAR
Aug 27, 2026	David W. Gryska - Director	Other	Common Stock	5,940	-^{footnote F1}	-
Aug 27, 2026	David W. Gryska - Director	Derivative	Stock Option (right to buy)	2,000	-^{footnote F2}	-
Aug 27, 2026	David W. Gryska - Director	Derivative	Stock Option (right to buy)	1,000	-^{footnote F2}	-
Aug 27, 2026	David W. Gryska - Director	Derivative	Stock Option (right to buy)]	2,000	-^{footnote F2}	-
Aug 27, 2026	David W. Gryska - Director	Derivative	Stock Option (right to buy)	31,000	-^{footnote F2}	-
Aug 27, 2026	David W. Gryska - Director	Derivative	Restricted Stock Units	18,353	-^{footnote F4}	-
Footnote F1 (price): Pursuant to the Agreement and Plan of Merger, dated July 26, 2026 (the "Merger Agreement"), by and among Forte Biosciences, Inc. ("Company"), argenx BV ("Parent"), and Avena Merger Sub Inc., a wholly owned subsidiary of Parent ("Purchaser"), the shares of common stock of Company… Full note on SEC EDGAR Footnote F2 (price): Pursuant to the Merger Agreement, each unexercised and outstanding option to purchase shares of Common Stock (a "Company Option"), whether or not vested, and which had a per share exercise price that was less than the Merger Consideration, was canceled and converted into the… Full note on SEC EDGAR Footnote F4 (price): Pursuant to the Merger Agreement, each outstanding restricted stock unit (a "Company RSU"), whether or not vested, was canceled and converted into the right of the holder to receive (i) (subject to any applicable withholding taxes) a lump-sum cash payment equal to (x) the Merger… Full note on SEC EDGAR
Aug 27, 2026	Richard G. Vincent - Director	Derivative	Stock Option (right to buy)	2,000	-^{footnote F1,F2}	-
Aug 27, 2026	Richard G. Vincent - Director	Derivative	Stock Option (right to buy)	31,000	-^{footnote F1,F2}	-
Aug 27, 2026	Richard G. Vincent - Director	Derivative	Restricted Stock Units	18,353	-^{footnote F4}	-
Footnote F1 (price): Pursuant to the Agreement and Plan of Merger, dated July 26, 2026 (the "Merger Agreement"), by and among Forte Biosciences, Inc. ("Company"), argenx BV ("Parent"), and Avena Merger Sub Inc., a wholly owned subsidiary of Parent ("Purchaser"), each unexercised and outstanding… Full note on SEC EDGAR Footnote F2 (price): At the effective time of the Merger, each Company Option that is then outstanding and unexercised, whether or not vested and which has a per share exercise price that is equal to or greater than the Merger Consideration, shall be cancelled with no consideration payable therefor. Footnote F4 (price): Pursuant to the Merger Agreement, each outstanding restricted stock unit (a "Company RSU"), whether or not vested, was canceled and converted into the right of the holder to receive (i) (subject to any applicable withholding taxes) a lump-sum cash payment equal to (x) the Merger… Full note on SEC EDGAR
Aug 27, 2026	Barbara K. Finck - Director	Derivative	Stock Option (right to buy)	2,000	-^{footnote F1,F2}	-
Aug 27, 2026	Barbara K. Finck - Director	Derivative	Stock Option (right to buy)]	166	-^{footnote F1,F2}	-
Aug 27, 2026	Barbara K. Finck - Director	Derivative	Stock Option (right to buy)	1,000	-^{footnote F1,F2}	-
Aug 27, 2026	Barbara K. Finck - Director	Derivative	Stock Option (right to buy)	1,000	-^{footnote F1,F2}	-
Aug 27, 2026	Barbara K. Finck - Director	Derivative	Stock Option (right to buy)	7,000	-^{footnote F1,F2}	-
Aug 27, 2026	Barbara K. Finck - Director	Derivative	Stock Option (right to buy)	31,000	-^{footnote F1,F2}	-
Aug 27, 2026	Barbara K. Finck - Director	Derivative	Restricted Stock Units	18,353	-^{footnote F4}	-
Footnote F1 (price): Pursuant to the Agreement and Plan of Merger, dated July 26, 2026 (the "Merger Agreement"), by and among Forte Biosciences, Inc. ("Company"), argenx BV ("Parent"), and Avena Merger Sub Inc., a wholly owned subsidiary of Parent ("Purchaser"), each unexercised and outstanding… Full note on SEC EDGAR Footnote F2 (price): At the effective time of the Merger, each Company Option that is then outstanding and unexercised, whether or not vested and which has a per share exercise price that is equal to or greater than the Merger Consideration, shall be cancelled with no consideration payable therefor. Footnote F4 (price): Pursuant to the Merger Agreement, each outstanding restricted stock unit (a "Company RSU"), whether or not vested, was canceled and converted into the right of the holder to receive (i) (subject to any applicable withholding taxes) a lump-sum cash payment equal to (x) the Merger… Full note on SEC EDGAR
Aug 27, 2026	Shivpreet Singh Kapoor - Director	Derivative	Stock Option (right to buy)	2,000	-^{footnote F1,F2}	-
Aug 27, 2026	Shivpreet Singh Kapoor - Director	Derivative	Stock Option (right to buy)	31,000	-^{footnote F1,F2}	-
Aug 27, 2026	Shivpreet Singh Kapoor - Director	Derivative	Restricted Stock Units	18,353	-^{footnote F4}	-
Footnote F1 (price): Pursuant to the Agreement and Plan of Merger, dated July 26, 2026 (the "Merger Agreement"), by and among Forte Biosciences, Inc. ("Company"), argenx BV ("Parent"), and Avena Merger Sub Inc., a wholly owned subsidiary of Parent ("Purchaser"), each unexercised and outstanding… Full note on SEC EDGAR Footnote F2 (price): At the effective time of the Merger, each Company Option that is then outstanding and unexercised, whether or not vested and which has a per share exercise price that is equal to or greater than the Merger Consideration, shall be cancelled with no consideration payable therefor. Footnote F4 (price): Pursuant to the Merger Agreement, each outstanding restricted stock unit (a "Company RSU"), whether or not vested, was canceled and converted into the right of the holder to receive (i) (subject to any applicable withholding taxes) a lump-sum cash payment equal to (x) the Merger… Full note on SEC EDGAR
Aug 27, 2026	Stephen K. Doberstein - Director	Derivative	Stock Option (right to buy)	2,000	-^{footnote F1,F2}	-
Aug 27, 2026	Stephen K. Doberstein - Director	Derivative	Stock Option (right to buy)	1,000	-^{footnote F1,F2}	-
Aug 27, 2026	Stephen K. Doberstein - Director	Derivative	Stock Option (right to buy)	1,000	-^{footnote F1,F2}	-
Aug 27, 2026	Stephen K. Doberstein - Director	Derivative	Stock Option (right to buy)	2,000	-^{footnote F1,F2}	-
Aug 27, 2026	Stephen K. Doberstein - Director	Derivative	Stock Option (right to buy)	31,000	-^{footnote F1,F2}	-
Aug 27, 2026	Stephen K. Doberstein - Director	Derivative	Restricted Stock Units	18,353	-^{footnote F4}	-
Footnote F1 (price): Pursuant to the Agreement and Plan of Merger, dated July 26, 2026 (the "Merger Agreement"), by and among Forte Biosciences, Inc. ("Company"), argenx BV ("Parent"), and Avena Merger Sub Inc., a wholly owned subsidiary of Parent ("Purchaser"), each unexercised and outstanding… Full note on SEC EDGAR Footnote F2 (price): At the effective time of the Merger, each Company Option that is then outstanding and unexercised, whether or not vested and which has a per share exercise price that is equal to or greater than the Merger Consideration, shall be cancelled with no consideration payable therefor. Footnote F4 (price): Pursuant to the Merger Agreement, each outstanding restricted stock unit (a "Company RSU"), whether or not vested, was canceled and converted into the right of the holder to receive (i) (subject to any applicable withholding taxes) a lump-sum cash payment equal to (x) the Merger… Full note on SEC EDGAR
Aug 27, 2026	Antony A. Riley - Officer	Other	Common Stock	42,600	-^{footnote F1}	-
Aug 27, 2026	Antony A. Riley - Officer	Derivative	Stock Option (right to buy)	421	-^{footnote F2}	-
Aug 27, 2026	Antony A. Riley - Officer	Derivative	Stock Option (right to buy)	2,999	-^{footnote F2}	-
Aug 27, 2026	Antony A. Riley - Officer	Derivative	Stock Option (right to buy)	1,700	-^{footnote F2}	-
Aug 27, 2026	Antony A. Riley - Officer	Derivative	Stock Option (right to buy)	2,999	-^{footnote F2}	-
Aug 27, 2026	Antony A. Riley - Officer	Derivative	Stock Option (right to buy)	14,000	-^{footnote F2}	-
Aug 27, 2026	Antony A. Riley - Officer	Derivative	Stock Option (right to buy)	323,000	-^{footnote F2}	-
Aug 27, 2026	Antony A. Riley - Officer	Derivative	Stock Option (right to buy)	90,000	-^{footnote F2}	-
Aug 27, 2026	Antony A. Riley - Officer	Derivative	Stock Option (right to buy)	22,000	-^{footnote F2}	-
Aug 27, 2026	Antony A. Riley - Officer	Derivative	Restricted Stock Units	750	-^{footnote F4}	-
Aug 27, 2026	Antony A. Riley - Officer	Derivative	Restricted Stock Units	60,000	-^{footnote F4}	-
Aug 27, 2026	Antony A. Riley - Officer	Derivative	Restricted Stock Units	2,976	-^{footnote F4}	-
Footnote F1 (price): Pursuant to the Agreement and Plan of Merger, dated July 26, 2026 (the "Merger Agreement"), by and among Forte Biosciences, Inc. ("Company"), argenx BV ("Parent"), and Avena Merger Sub Inc., a wholly owned subsidiary of Parent ("Purchaser"), the shares of common stock of Company… Full note on SEC EDGAR Footnote F2 (price): Pursuant to the Merger Agreement, each unexercised and outstanding option to purchase shares of Common Stock (a "Company Option"), whether or not vested, and which had a per share exercise price that was less than the Merger Consideration, was canceled and converted into the… Full note on SEC EDGAR Footnote F4 (price): Pursuant to the Merger Agreement, each outstanding restricted stock unit (a "Company RSU"), whether or not vested, was canceled and converted into the right of the holder to receive (i) (subject to any applicable withholding taxes) a lump-sum cash payment equal to (x) the Merger… Full note on SEC EDGAR
Aug 27, 2026	Paul A. Wagner - Officer	Other	Common Stock	85,482	-^{footnote F1}	-
Aug 27, 2026	Paul A. Wagner - Officer	Derivative	Stock Option (right to buy)	16,866	-^{footnote F2}	-
Aug 27, 2026	Paul A. Wagner - Officer	Derivative	Stock Option (right to buy)	5,400	-^{footnote F2}	-
Aug 27, 2026	Paul A. Wagner - Officer	Derivative	Stock Option (right to buy)	11,999	-^{footnote F2}	-
Aug 27, 2026	Paul A. Wagner - Officer	Derivative	Stock Option (right to buy)	44,000	-^{footnote F2}	-
Aug 27, 2026	Paul A. Wagner - Officer	Derivative	Stock Option (right to buy)	920,000	-^{footnote F2}	-
Aug 27, 2026	Paul A. Wagner - Officer	Derivative	Stock Option (right to buy)	270,000	-^{footnote F2}	-
Aug 27, 2026	Paul A. Wagner - Officer	Derivative	Stock Option (right to buy)	500,000	-^{footnote F2}	-
Aug 27, 2026	Paul A. Wagner - Officer	Derivative	Restricted Stock Units	2,500	-^{footnote F4}	-
Aug 27, 2026	Paul A. Wagner - Officer	Derivative	Restricted Stock Units	180,000	-^{footnote F4}	-
Aug 27, 2026	Paul A. Wagner - Officer	Derivative	Restricted Stock Units	3,511	-^{footnote F4}	-
Footnote F1 (price): Pursuant to the Agreement and Plan of Merger, dated July 26, 2026 (the "Merger Agreement"), by and among Forte Biosciences, Inc. ("Company"), argenx BV ("Parent"), and Avena Merger Sub Inc., a wholly owned subsidiary of Parent ("Purchaser"), the shares of common stock of Company… Full note on SEC EDGAR Footnote F2 (price): Pursuant to the Merger Agreement, each unexercised and outstanding option to purchase shares of Common Stock (a "Company Option"), whether or not vested, and which had a per share exercise price that was less than the Merger Consideration, was canceled and converted into the… Full note on SEC EDGAR Footnote F4 (price): Pursuant to the Merger Agreement, each outstanding restricted stock unit (a "Company RSU"), whether or not vested, was canceled and converted into the right of the holder to receive (i) (subject to any applicable withholding taxes) a lump-sum cash payment equal to (x) the Merger… Full note on SEC EDGAR
Jul 1, 2026	Antony A. Riley - Officer	Option exercise	Common Stock	375	-^{footnote F1}	-
Jul 1, 2026	Antony A. Riley - Officer	Tax withholding / forfeiture	Common Stock	134	$21.32	$3K
Jul 1, 2026	Antony A. Riley - Officer	Option exercise	Restricted Stock Units	375	$0.00	-
Footnote F1 (price): Each restricted stock unit ("RSU") represents a contingent right to receive one share of Forte Biosciences, Inc. (the "Issuer") Common Stock.
Jul 1, 2026	Paul A. Wagner - Officer	Tax withholding / forfeiture	Common Stock	98	$21.32	$2K
Jul 1, 2026	Paul A. Wagner - Officer	Option exercise	Common Stock	1,250	-^{footnote F1}	-
Jul 1, 2026	Paul A. Wagner - Officer	Option exercise	Restricted Stock Units	1,250	$0.00	-
Footnote F1 (price): Each restricted stock unit ("RSU") represents a contingent right to receive one share of Forte Biosciences, Inc. (the "Issuer") Common Stock.
Jun 16, 2026	Antony A. Riley - Officer	Grant or award	Stock Option (right to buy)	22,000	$0.00	-
Jun 16, 2026	Paul A. Wagner - Officer	Grant or award	Stock Option (right to buy)	500,000	$0.00	-
May 29, 2026	Stephen K. Doberstein	Grant or award	Restricted Stock Units	18,353	$0.00	-
May 29, 2026	Shivpreet Singh Kapoor	Grant or award	Restricted Stock Units	18,353	$0.00	-
May 29, 2026	Richard G. Vincent	Grant or award	Restricted Stock Units	18,353	$0.00	-
May 29, 2026	David W. Gryska	Grant or award	Restricted Stock Units	18,353	$0.00	-
May 29, 2026	Scott C. Brun	Grant or award	Restricted Stock Units	18,353	$0.00	-
May 29, 2026	Steven Kornfeld	Grant or award	Restricted Stock Units	18,353	$0.00	-
Apr 1, 2026	Antony A. Riley - Officer	Tax withholding / forfeiture	Common Stock	134	$24.86	$3K
Apr 1, 2026	Antony A. Riley - Officer	Option exercise	Common Stock	375	-^{footnote F1}	-
Apr 1, 2026	Antony A. Riley - Officer	Option exercise	Restricted Stock Units	375	$0.00	-
Footnote F1 (price): Each restricted stock unit ("RSU") represents a contingent right to receive one share of Forte Biosciences, Inc. (the "Issuer") Common Stock.
Apr 1, 2026	Paul A. Wagner - Officer	Tax withholding / forfeiture	Common Stock	98	$24.86	$2K
Apr 1, 2026	Paul A. Wagner - Officer	Option exercise	Common Stock	1,250	-^{footnote F1}	-
Apr 1, 2026	Paul A. Wagner - Officer	Option exercise	Restricted Stock Units	1,250	$0.00	-
Footnote F1 (price): Each restricted stock unit ("RSU") represents a contingent right to receive one share of Forte Biosciences, Inc. (the "Issuer") Common Stock.
Jan 12, 2026	Antony A. Riley - Officer	Grant or award	Stock Option (right to buy)	90,000	$0.00	-
Jan 12, 2026	Antony A. Riley - Officer	Grant or award	Restricted Stock Units	60,000	$0.00	-
Jan 12, 2026	Paul A. Wagner - Officer	Grant or award	Stock Option (right to buy)	270,000	$0.00	-
Jan 12, 2026	Paul A. Wagner - Officer	Grant or award	Restricted Stock Units	180,000	$0.00	-
Oct 1, 2025	Paul A. Wagner - Officer	Tax withholding / forfeiture	Common Stock	98	$14.52	$1K
Oct 1, 2025	Paul A. Wagner - Officer	Option exercise	Common Stock	1,250	$0.00^{footnote F1}	-
Oct 1, 2025	Paul A. Wagner - Officer	Option exercise	Restricted Stock Units	1,250	$0.00	-
Footnote F1 (price): Each restricted stock unit ("RSU") represents a contingent right to receive one share of Forte Biosciences, Inc. (the "Issuer") Common Stock.
Oct 1, 2025	Antony A. Riley - Officer	Option exercise	Common Stock	375	$0.00^{footnote F1}	-
Oct 1, 2025	Antony A. Riley - Officer	Tax withholding / forfeiture	Common Stock	134	$14.52	$2K
Oct 1, 2025	Antony A. Riley - Officer	Option exercise	Restricted Stock Units	375	$0.00	-
Footnote F1 (price): Each restricted stock unit ("RSU") represents a contingent right to receive one share of Forte Biosciences, Inc. (the "Issuer") Common Stock.
Jul 1, 2025	Paul A. Wagner - Officer	Option exercise	Common Stock	1,250	$0.00	-
Jul 1, 2025	Paul A. Wagner - Officer	Tax withholding / forfeiture	Common Stock	98	$12.44	$1K
Jul 1, 2025	Paul A. Wagner - Officer	Option exercise	Restricted Stock Units	1,250	$0.00	-
Jul 1, 2025	Antony A. Riley - Officer	Option exercise	Common Stock	375	$0.00	-
Jul 1, 2025	Antony A. Riley - Officer	Tax withholding / forfeiture	Common Stock	134	$12.44	$2K
Jul 1, 2025	Antony A. Riley - Officer	Option exercise	Restricted Stock Units	375	$0.00	-
Nov 21, 2024	Antony A. Riley - Officer	Open-market purchase	Common Stock	22,514	$5.55	$125K
Oct 1, 2024	Paul A. Wagner - Officer	Option exercise	Common Stock	1,250	$0.00	-
Oct 1, 2024	Paul A. Wagner - Officer	Tax withholding / forfeiture	Common Stock	98	$5.16	$506
Oct 1, 2024	Paul A. Wagner - Officer	Option exercise	Restricted Stock Units	1,250	$0.00	-
Oct 1, 2024	Antony A. Riley - Officer	Option exercise	Common Stock	375	$0.00	-
Oct 1, 2024	Antony A. Riley - Officer	Tax withholding / forfeiture	Common Stock	133	$5.16	$686
Oct 1, 2024	Antony A. Riley - Officer	Option exercise	Restricted Stock Units	375	$0.00	-

Recent FBRX Form 8-K filings

Read FBRX company news

Aug 27, 2026Item 2.01, 3.01, 3.03, 5.01, 5.02, 5.03, 9.01

Read the filing on SEC EDGAR

Jul 27, 2026Item 1.01, 7.01, 9.01

Read the filing on SEC EDGAR

Jul 9, 2026Item 7.01, 8.01, 9.01

Read the filing on SEC EDGAR

Jun 2, 2026Item 5.02, 5.07, 9.01

FBRX insider trading FAQ

What is the latest insider trade for FBRX?

Forte Biosciences, Inc. (FBRX) had 9 insider filings in the last 90 days, with the most recent on 2026-08-27. The full record for FBRX runs to 30 Form 4 filings, the earliest from 2024-10-02. InsiderAlpha adds new Form 4, Form 144 and 8-K filings as they arrive from SEC EDGAR.

How many insiders are buying FBRX stock?

No insider purchases of FBRX were filed in the last 90 days. 1 purchase is on record for this company.

How many insiders are selling FBRX stock?

No insider sales of FBRX were filed in the last 90 days.

Where can I see FBRX SEC filings (Form 4, 10-K, 10-Q, 8-K)?

This page collects FBRX Form 4 insider transactions, Form 144 sale notices and 8-K filings in one place. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.

More Health Care companies with insider activity

Recent insider filings

The EDGAR links open each original Form 4, so you can check any number on this page against the filing it came from.

Aug 27, 2026 - Steven Kornfeld view on EDGAR
Aug 27, 2026 - Scott C. Brun view on EDGAR
Aug 27, 2026 - David W. Gryska view on EDGAR
Aug 27, 2026 - Richard G. Vincent view on EDGAR
Aug 27, 2026 - Barbara K. Finck view on EDGAR
Aug 27, 2026 - Shivpreet Singh Kapoor view on EDGAR
Aug 27, 2026 - Stephen K. Doberstein view on EDGAR
Aug 27, 2026 - Antony A. Riley view on EDGAR
Aug 27, 2026 - Paul A. Wagner view on EDGAR

Related companies with recent insider activity

Learn more

What the Form 4 transaction codes mean: Grants, option exercises, gifts and tax withholding are not trades on the market. The codes say which is which.
Insider activity in Health Care: Where FBRX's peers are being bought and sold.
Every recent Form 4: The market-wide feed, updated as filings arrive from SEC EDGAR.

Follow FBRX with a 7-day demo

FBRX on your watchlist
Every FBRX Form 4 filing on record
Up to 3 months of FBRX price history
The daily trading plan of ranked insider buys, on a delay, with the plan archive

Start 7-day demoCard required. Your card is never charged for the demo.

Form 4 transaction type

Transactions

Total value

Derivative transaction

2,858,758

Other acquisition / disposition

137,982

Date

Insider

Transaction

Security

Price

Value

Aug 27, 2026

Steven Kornfeld - Director

Other

Common Stock

3,960

-^{footnote F1}

Aug 27, 2026

Steven Kornfeld - Director

Derivative

Stock Option (right to buy)

1,200

-^{footnote F2}

Aug 27, 2026

Steven Kornfeld - Director

Derivative

Stock Option (right to buy)

800

-^{footnote F2}

Aug 27, 2026

Steven Kornfeld - Director

Derivative

Stock Option (right to buy)

1,000

-^{footnote F2}

Aug 27, 2026

Steven Kornfeld - Director

Derivative

Stock Option (right to buy)

1,000

-^{footnote F2}

Aug 27, 2026

Steven Kornfeld - Director

Derivative

Stock Option (right to buy)

1,000

-^{footnote F2}

Aug 27, 2026

Steven Kornfeld - Director

Derivative

Stock Option (right to buy)

2,000

-^{footnote F2}

Aug 27, 2026

Steven Kornfeld - Director

Derivative

Stock Option (right to buy)

31,000

-^{footnote F2}

Aug 27, 2026

Steven Kornfeld - Director

Derivative

Restricted Stock Units

18,353

-^{footnote F4}

Footnote F1 (price): Pursuant to the Agreement and Plan of Merger, dated July 26, 2026 (the "Merger Agreement"), by and among Forte Biosciences, Inc. ("Company"), argenx BV ("Parent"), and Avena Merger Sub Inc., a wholly owned subsidiary of Parent ("Purchaser"), the shares of common stock of Company… Full note on SEC EDGAR
Footnote F2 (price): Pursuant to the Merger Agreement, each unexercised and outstanding option to purchase shares of Common Stock (a "Company Option"), whether or not vested, and which had a per share exercise price that was less than the Merger Consideration, was canceled and converted into the… Full note on SEC EDGAR
Footnote F4 (price): Pursuant to the Merger Agreement, each outstanding restricted stock unit (a "Company RSU"), whether or not vested, was canceled and converted into the right of the holder to receive (i) (subject to any applicable withholding taxes) a lump-sum cash payment equal to (x) the Merger… Full note on SEC EDGAR

Aug 27, 2026

Scott C. Brun - Director

Derivative

Stock Option (right to buy)

2,000

-^{footnote F1,F2}

Aug 27, 2026

Scott C. Brun - Director

Derivative

Stock Option (right to buy)

1,000

-^{footnote F1,F2}

Aug 27, 2026

Scott C. Brun - Director

Derivative

Stock Option (right to buy)

2,000

-^{footnote F1,F2}

Aug 27, 2026

Scott C. Brun - Director

Derivative

Stock Option (right to buy)

31,000

-^{footnote F1,F2}

Aug 27, 2026

Scott C. Brun - Director

Derivative

Restricted Stock Units

18,353

-^{footnote F4}

Footnote F1 (price): Pursuant to the Agreement and Plan of Merger, dated July 26, 2026 (the "Merger Agreement"), by and among Forte Biosciences, Inc. ("Company"), argenx BV ("Parent"), and Avena Merger Sub Inc., a wholly owned subsidiary of Parent ("Purchaser"), each unexercised and outstanding… Full note on SEC EDGAR
Footnote F2 (price): At the effective time of the Merger, each Company Option that is then outstanding and unexercised, whether or not vested and which has a per share exercise price that is equal to or greater than the Merger Consideration, shall be cancelled with no consideration payable therefor.
Footnote F4 (price): Pursuant to the Merger Agreement, each outstanding restricted stock unit (a "Company RSU"), whether or not vested, was canceled and converted into the right of the holder to receive (i) (subject to any applicable withholding taxes) a lump-sum cash payment equal to (x) the Merger… Full note on SEC EDGAR

Aug 27, 2026

David W. Gryska - Director

Other

Common Stock

5,940

-^{footnote F1}

Aug 27, 2026

David W. Gryska - Director

Derivative

Stock Option (right to buy)

2,000

-^{footnote F2}

Aug 27, 2026

David W. Gryska - Director

Derivative

Stock Option (right to buy)

1,000

-^{footnote F2}

Aug 27, 2026

David W. Gryska - Director

Derivative

Stock Option (right to buy)]

2,000

-^{footnote F2}

Aug 27, 2026

David W. Gryska - Director

Derivative

Stock Option (right to buy)

31,000

-^{footnote F2}

Aug 27, 2026

David W. Gryska - Director

Derivative

Restricted Stock Units

18,353

-^{footnote F4}

Footnote F1 (price): Pursuant to the Agreement and Plan of Merger, dated July 26, 2026 (the "Merger Agreement"), by and among Forte Biosciences, Inc. ("Company"), argenx BV ("Parent"), and Avena Merger Sub Inc., a wholly owned subsidiary of Parent ("Purchaser"), the shares of common stock of Company… Full note on SEC EDGAR
Footnote F2 (price): Pursuant to the Merger Agreement, each unexercised and outstanding option to purchase shares of Common Stock (a "Company Option"), whether or not vested, and which had a per share exercise price that was less than the Merger Consideration, was canceled and converted into the… Full note on SEC EDGAR
Footnote F4 (price): Pursuant to the Merger Agreement, each outstanding restricted stock unit (a "Company RSU"), whether or not vested, was canceled and converted into the right of the holder to receive (i) (subject to any applicable withholding taxes) a lump-sum cash payment equal to (x) the Merger… Full note on SEC EDGAR

Aug 27, 2026

Richard G. Vincent - Director

Derivative

Stock Option (right to buy)

2,000

-^{footnote F1,F2}

Aug 27, 2026

Richard G. Vincent - Director

Derivative

Stock Option (right to buy)

31,000

-^{footnote F1,F2}

Aug 27, 2026

Richard G. Vincent - Director

Derivative

Restricted Stock Units

18,353

-^{footnote F4}

Footnote F1 (price): Pursuant to the Agreement and Plan of Merger, dated July 26, 2026 (the "Merger Agreement"), by and among Forte Biosciences, Inc. ("Company"), argenx BV ("Parent"), and Avena Merger Sub Inc., a wholly owned subsidiary of Parent ("Purchaser"), each unexercised and outstanding… Full note on SEC EDGAR
Footnote F2 (price): At the effective time of the Merger, each Company Option that is then outstanding and unexercised, whether or not vested and which has a per share exercise price that is equal to or greater than the Merger Consideration, shall be cancelled with no consideration payable therefor.
Footnote F4 (price): Pursuant to the Merger Agreement, each outstanding restricted stock unit (a "Company RSU"), whether or not vested, was canceled and converted into the right of the holder to receive (i) (subject to any applicable withholding taxes) a lump-sum cash payment equal to (x) the Merger… Full note on SEC EDGAR

Aug 27, 2026

Barbara K. Finck - Director

Derivative

Stock Option (right to buy)

2,000

-^{footnote F1,F2}

Aug 27, 2026

Barbara K. Finck - Director

Derivative

Stock Option (right to buy)]

166

-^{footnote F1,F2}

Aug 27, 2026

Barbara K. Finck - Director

Derivative

Stock Option (right to buy)

1,000

-^{footnote F1,F2}

Aug 27, 2026

Barbara K. Finck - Director

Derivative

Stock Option (right to buy)

1,000

-^{footnote F1,F2}

Aug 27, 2026

Barbara K. Finck - Director

Derivative

Stock Option (right to buy)

7,000

-^{footnote F1,F2}

Aug 27, 2026

Barbara K. Finck - Director

Derivative

Stock Option (right to buy)

31,000

-^{footnote F1,F2}

Aug 27, 2026

Barbara K. Finck - Director

Derivative

Restricted Stock Units

18,353

-^{footnote F4}

Footnote F1 (price): Pursuant to the Agreement and Plan of Merger, dated July 26, 2026 (the "Merger Agreement"), by and among Forte Biosciences, Inc. ("Company"), argenx BV ("Parent"), and Avena Merger Sub Inc., a wholly owned subsidiary of Parent ("Purchaser"), each unexercised and outstanding… Full note on SEC EDGAR
Footnote F2 (price): At the effective time of the Merger, each Company Option that is then outstanding and unexercised, whether or not vested and which has a per share exercise price that is equal to or greater than the Merger Consideration, shall be cancelled with no consideration payable therefor.
Footnote F4 (price): Pursuant to the Merger Agreement, each outstanding restricted stock unit (a "Company RSU"), whether or not vested, was canceled and converted into the right of the holder to receive (i) (subject to any applicable withholding taxes) a lump-sum cash payment equal to (x) the Merger… Full note on SEC EDGAR

Aug 27, 2026

Shivpreet Singh Kapoor - Director

Derivative

Stock Option (right to buy)

2,000

-^{footnote F1,F2}

Aug 27, 2026

Shivpreet Singh Kapoor - Director

Derivative

Stock Option (right to buy)

31,000

-^{footnote F1,F2}

Aug 27, 2026

Shivpreet Singh Kapoor - Director

Derivative

Restricted Stock Units

18,353

-^{footnote F4}

Footnote F1 (price): Pursuant to the Agreement and Plan of Merger, dated July 26, 2026 (the "Merger Agreement"), by and among Forte Biosciences, Inc. ("Company"), argenx BV ("Parent"), and Avena Merger Sub Inc., a wholly owned subsidiary of Parent ("Purchaser"), each unexercised and outstanding… Full note on SEC EDGAR
Footnote F2 (price): At the effective time of the Merger, each Company Option that is then outstanding and unexercised, whether or not vested and which has a per share exercise price that is equal to or greater than the Merger Consideration, shall be cancelled with no consideration payable therefor.
Footnote F4 (price): Pursuant to the Merger Agreement, each outstanding restricted stock unit (a "Company RSU"), whether or not vested, was canceled and converted into the right of the holder to receive (i) (subject to any applicable withholding taxes) a lump-sum cash payment equal to (x) the Merger… Full note on SEC EDGAR

Aug 27, 2026

Stephen K. Doberstein - Director

Derivative

Stock Option (right to buy)

2,000

-^{footnote F1,F2}

Aug 27, 2026

Stephen K. Doberstein - Director

Derivative

Stock Option (right to buy)

1,000

-^{footnote F1,F2}

Aug 27, 2026

Stephen K. Doberstein - Director

Derivative

Stock Option (right to buy)

1,000

-^{footnote F1,F2}

Aug 27, 2026

Stephen K. Doberstein - Director

Derivative

Stock Option (right to buy)

2,000

-^{footnote F1,F2}

Aug 27, 2026

Stephen K. Doberstein - Director

Derivative

Stock Option (right to buy)

31,000

-^{footnote F1,F2}

Aug 27, 2026

Stephen K. Doberstein - Director

Derivative

Restricted Stock Units

18,353

-^{footnote F4}

Footnote F1 (price): Pursuant to the Agreement and Plan of Merger, dated July 26, 2026 (the "Merger Agreement"), by and among Forte Biosciences, Inc. ("Company"), argenx BV ("Parent"), and Avena Merger Sub Inc., a wholly owned subsidiary of Parent ("Purchaser"), each unexercised and outstanding… Full note on SEC EDGAR
Footnote F2 (price): At the effective time of the Merger, each Company Option that is then outstanding and unexercised, whether or not vested and which has a per share exercise price that is equal to or greater than the Merger Consideration, shall be cancelled with no consideration payable therefor.
Footnote F4 (price): Pursuant to the Merger Agreement, each outstanding restricted stock unit (a "Company RSU"), whether or not vested, was canceled and converted into the right of the holder to receive (i) (subject to any applicable withholding taxes) a lump-sum cash payment equal to (x) the Merger… Full note on SEC EDGAR

Aug 27, 2026